Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy

Autor: Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M. Vanderbilt, Pooja Gogia, Antoine Desilets, Meriem Messaoudene, Daniel Kelly, Marc Ladanyi, Matthew D. Hellmann, Laurence Zitvogel, Charles M. Rudin, Bertrand Routy, Lisa Derosa, Adam J. Schoenfeld

Publikováno v: npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)

Abstract Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of antibiotics on clinical o

Externí odkaz: https://doaj.org/article/6b78137517bb4690816d94fa12584591

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Autor: Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)

Background Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not bee

Externí odkaz: https://doaj.org/article/1db67c48820e42a9b021621d9022be62

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

Autor: Roy S Herbst, Vamsidhar Velcheti, Mari Mino-Kenudson, Matthew D Hellmann, David L Rimm, Kurt A Schalper, Anant Madabhushi, Justin Gainor, Germán Corredor, Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, Ila J Datar, Cristian Barrera, Lindsey Behlman, Jonathan W Riess

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)

Externí odkaz: https://doaj.org/article/dd6140760c244b16852a5797f0cd5927

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

Autor: Kevin Litchfield, James L. Reading, Emilia L. Lim, Hang Xu, Po Liu, Maise Al-Bakir, Yien Ning Sophia Wong, Andrew Rowan, Samuel A. Funt, Taha Merghoub, David Perkins, Martin Lauss, Inge Marie Svane, Göran Jönsson, Javier Herrero, James Larkin, Sergio A. Quezada, Matthew D. Hellmann, Samra Turajlic, Charles Swanton

Publikováno v: Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)

The transcripts generated by frameshifts and indels in cancer are frequently degraded by nonsense mediated decay. Here, the authors show that some of these transcripts can escape this degradation mechanism and their prevalence correlates with tumour

Externí odkaz: https://doaj.org/article/5361db97aec7487d9e4b4732b41ccecf

Protein-altering germline mutations implicate novel genes related to lung cancer development

Autor: Xuemei Ji, Semanti Mukherjee, Maria Teresa Landi, Yohan Bosse, Philippe Joubert, Dakai Zhu, Ivan Gorlov, Xiangjun Xiao, Younghun Han, Olga Gorlova, Rayjean J. Hung, Yonathan Brhane, Robert Carreras-Torres, David C. Christiani, Neil Caporaso, Mattias Johansson, Geoffrey Liu, Stig E. Bojesen, Loic Le Marchand, Demetrios Albanes, Heike Bickeböller, Melinda C. Aldrich, William S. Bush, Adonina Tardon, Gad Rennert, Chu Chen, Jinyoung Byun, Konstantin H. Dragnev, John K. Field, Lambertus FA. Kiemeney, Philip Lazarus, Shan Zienolddiny, Stephen Lam, Matthew B. Schabath, Angeline S. Andrew, Pier A. Bertazzi, Angela C. Pesatori, Nancy Diao, Li Su, Lei Song, Ruyang Zhang, Natasha Leighl, Jakob S. Johansen, Anders Mellemgaard, Walid Saliba, Christopher Haiman, Lynne Wilkens, Ana Fernandez-Somoano, Guillermo Fernandez-Tardon, Erik H. F. M. van der Heijden, Jin Hee Kim, Michael P. A. Davies, Michael W. Marcus, Hans Brunnström, Jonas Manjer, Olle Melander, David C. Muller, Kim Overvad, Antonia Trichopoulou, Rosario Tumino, Gary E. Goodman, Angela Cox, Fiona Taylor, Penella Woll, Erich Wichmann, Thomas Muley, Angela Risch, Albert Rosenberger, Kjell Grankvist, Mikael Johansson, Frances Shepherd, Ming-Sound Tsao, Susanne M. Arnold, Eric B. Haura, Ciprian Bolca, Ivana Holcatova, Vladimir Janout, Milica Kontic, Jolanta Lissowska, Anush Mukeria, Simona Ognjanovic, Tadeusz M. Orlowski, Ghislaine Scelo, Beata Swiatkowska, David Zaridze, Per Bakke, Vidar Skaug, Lesley M. Butler, Kenneth Offit, Preethi Srinivasan, Chaitanya Bandlamudi, Matthew D. Hellmann, David B. Solit, Mark E. Robson, Charles M. Rudin, Zsofia K. Stadler, Barry S. Taylor, Michael F. Berger, Richard Houlston, John McLaughlin, Victoria Stevens, David C. Nickle, Ma’en Obeidat, Wim Timens, María Soler Artigas, Sanjay Shete, Hermann Brenner, Stephen Chanock, Paul Brennan, James D. McKay, Christopher I. Amos

Publikováno v: Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)

In lung cancer, relatively few germline mutations are known to impact risk. Here the authors looked at rare variants in 39,146 individuals and find novel germline mutations associated with risk, as well as implicating ATM and a new candidate gene for

Externí odkaz: https://doaj.org/article/98db56edb20d4123b824401859c438ab